This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Chemotherapy for advanced epithelial ovarian cancer
Hematology/Oncology Clinics of North America. 1992 ;6(4) :879-894
AbstractIn the past decade there have been significant improvements in chemotherapy for advanced ovarian cancer. Platinum-based chemotherapy has improved response rates and, to a lesser degree, prolonged survival. Taxol and its combination with platinum drugs holds the promise for even further improvements in survival. Clinical trials are evaluating issues such as dose- intensity, new combinations, and drug resistance.
Notes08898588 (ISSN) Cited By: 14; Export Date: 31 May 2006; Source: Scopus CODEN: HCNAE Language of Original Document: English Correspondence Address: Ozols, R.F.; Department of Medical Oncology; Fox Chase Cancer Center; 7701 Burholme Avenue Philadelphia, PA 19111, United States Chemicals/CAS: altretamine, 15468-34-5, 2975-00-0, 645-05-6; carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; cyclophosphamide, 50-18-0; doxorubicin, 23214-92-8, 25316-40-9; ifosfamide, 3778-73-2, Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols